应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
PTHS PELTHOS THERAPEUTICS INC
休市中 01-23 16:00:00 EST
24.75
+0.40
+1.64%
盘后
24.75
+0.00
0.00%
16:04 EST
最高
24.75
最低
23.00
成交量
7,336
今开
23.00
昨收
24.35
日振幅
7.19%
总市值
7,578万
流通市值
6,492万
总股本
306.17万
成交额
17.41万
换手率
0.28%
流通股本
262.31万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Pelthos Therapeutics公司融资将用于支持Zelsuvmi商业化,并推动Xepi与Xeglyze上市
美股速递 · 01-13
Pelthos Therapeutics公司融资将用于支持Zelsuvmi商业化,并推动Xepi与Xeglyze上市
Pelthos Therapeutics Inc.盘中异动 大幅上涨5.69%报29.00美元
市场透视 · 01-08
Pelthos Therapeutics Inc.盘中异动 大幅上涨5.69%报29.00美元
Pelthos Therapeutics 签署重要的药品福利管理协议 扩大患者对 Zelsuvmi™ (Berdazimer) 外用凝胶的获取
美股速递 · 2025-12-04
Pelthos Therapeutics 签署重要的药品福利管理协议 扩大患者对 Zelsuvmi™ (Berdazimer) 外用凝胶的获取
佩尔索斯治疗公司获得Xepi乳膏在美国的独家营销权Pelthos Therapeutics Secures Exclusive U.S. Marketing Rights for Xepi Cream
动脉网 · 2025-11-10
佩尔索斯治疗公司获得Xepi乳膏在美国的独家营销权Pelthos Therapeutics Secures Exclusive U.S. Marketing Rights for Xepi Cream
Pelthos Therapeutics收购Xepi®(Ozenoxacin)乳膏1%并宣布1800万美元的私人可转换票据融资
美股速递 · 2025-11-07
Pelthos Therapeutics收购Xepi®(Ozenoxacin)乳膏1%并宣布1800万美元的私人可转换票据融资
Pelthos Therapeutics Inc向SEC提交申请:现有股东拟发行最多814万股普通股
美股速递 · 2025-08-29
Pelthos Therapeutics Inc向SEC提交申请:现有股东拟发行最多814万股普通股
加载更多
公司概况
公司名称:
PELTHOS THERAPEUTICS INC
所属市场:
AMEX
上市日期:
--
主营业务:
Pelthos Therapeutics Inc.是一家于2021年3月19日成立的内华达公司。该公司是一家临床阶段的生物技术公司,专注于开发和商业化缓解疼痛的新疗法。该公司的临床重点是选择性靶向钠离子通道,即“NaV1.7”,以及NaV家族中的其他受体。NaV1.7在人类生理学中已被基因验证为疼痛受体。遗传学研究表明,具有某种遗传性NaV1.7调节的家庭始终表现出不感到疼痛的病理学。
发行价格:
--
{"stockData":{"symbol":"PTHS","market":"US","secType":"STK","nameCN":"PELTHOS THERAPEUTICS INC","latestPrice":24.75,"timestamp":1769202000000,"preClose":24.35,"halted":0,"volume":7336,"hourTrading":{"tag":"盘后","latestPrice":24.75,"preClose":24.75,"latestTime":"16:04 EST","volume":1,"amount":24.75,"timestamp":1769202260289,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01642710472279255,"floatShares":2623100,"shares":3061681,"eps":-19.070698,"marketStatus":"休市中","change":0.4,"latestTime":"01-23 16:00:00 EST","open":23,"high":24.75,"low":23,"amount":174101.091808,"amplitude":0.071869,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-19.070698,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1769418000000},"marketStatusCode":7,"adr":0,"listingDate":1708059600000,"exchange":"AMEX","adjPreClose":24.35,"postHourTrading":{"tag":"盘后","latestPrice":24.75,"preClose":24.75,"latestTime":"16:04 EST","volume":1,"amount":24.75,"timestamp":1769202260289,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.574426432192813},"requestUrl":"/m/hq/s/PTHS","defaultTab":"news","newsList":[{"id":"1188848364","title":"Pelthos Therapeutics公司融资将用于支持Zelsuvmi商业化,并推动Xepi与Xeglyze上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1188848364","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188848364?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:34","pubTimestamp":1768311298,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics Inc. 近期成功获得融资,其募集资金将主要用于加速其核心产品Zelsuvmi的商业化进程。与此同时,公司也计划利用这笔资金正式推出另外两款重要产品——Xepi和Xeglyze,以进一步拓展其产品管线并巩固其在治疗领域的市场地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4135","PTHS","HRZN"],"gpt_icon":0},{"id":"2601833250","title":"Pelthos Therapeutics Inc.盘中异动 大幅上涨5.69%报29.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601833250","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601833250?lang=zh_cn&edition=full","pubTime":"2026-01-08 03:43","pubTimestamp":1767815022,"startTime":"0","endTime":"0","summary":"北京时间2026年01月08日03时43分,Pelthos Therapeutics Inc.股票出现异动,股价快速上涨5.69%。截至发稿,该股报29.00美元/股,成交量6264股,换手率0.20%,振幅3.86%。Pelthos Therapeutics Inc.股票所在的生物技术行业中,整体涨幅为2.04%。Pelthos Therapeutics Inc.公司简介:Pelthos Therapeutics Inc是一家临床阶段的生物技术公司,开发和商业化新型,非阿片类,非成瘾性治疗来减轻疼痛。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010803434297a13597&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010803434297a13597&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PTHS","LENZ","BK4539","BK4007","BK4139"],"gpt_icon":0},{"id":"1198778700","title":"Pelthos Therapeutics 签署重要的药品福利管理协议 扩大患者对 Zelsuvmi™ (Berdazimer) 外用凝胶的获取","url":"https://stock-news.laohu8.com/highlight/detail?id=1198778700","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198778700?lang=zh_cn&edition=full","pubTime":"2025-12-04 20:01","pubTimestamp":1764849670,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics 签署重要的药品福利管理协议,扩大患者对 Zelsuvmi™ (Berdazimer) 外用凝胶的获取,10.3%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTHS","BK4139"],"gpt_icon":0},{"id":"2582381023","title":"佩尔索斯治疗公司获得Xepi乳膏在美国的独家营销权Pelthos Therapeutics Secures Exclusive U.S. Marketing Rights for Xepi Cream","url":"https://stock-news.laohu8.com/highlight/detail?id=2582381023","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582381023?lang=zh_cn&edition=full","pubTime":"2025-11-10 18:09","pubTimestamp":1762769340,"startTime":"0","endTime":"0","summary":"此协议授予Pelthos在美国境内对Xepi的分销和商业化的控制权。Xepi Cream, which contains 1% ozenoxacin, is used as an antimicrobial treatment for skin infections. The acquisition involves transferring marketing rights from Biofrontera and Ferrer to Pelthos Therapeutics, allowing the company to oversee its availability and promotion across the country.含有1%奥泽诺沙星的Xepi乳膏被用作皮肤感染的抗菌治疗。此次收购涉及将Xepi的营销权从Biofrontera和Ferrer转移至Pelthos Therapeutics,使该公司能够在全国范围内监督其供应与推广。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111018112494fb2a80&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111018112494fb2a80&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PTHS","BK4539","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"1131527726","title":"Pelthos Therapeutics收购Xepi®(Ozenoxacin)乳膏1%并宣布1800万美元的私人可转换票据融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1131527726","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131527726?lang=zh_cn&edition=full","pubTime":"2025-11-07 21:00","pubTimestamp":1762520410,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics收购Xepi®(Ozenoxacin)乳膏1%并宣布1800万美元的私人可转换票据融资","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTHS"],"gpt_icon":0},{"id":"1118849151","title":"Pelthos Therapeutics Inc向SEC提交申请:现有股东拟发行最多814万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1118849151","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118849151?lang=zh_cn&edition=full","pubTime":"2025-08-29 04:09","pubTimestamp":1756411765,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics Inc向美国证券交易委员会提交申报文件,申请由现有股东发行最多814万股普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTHS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chromocell.com","stockEarnings":[{"period":"1week","weight":0.0733},{"period":"1month","weight":-0.066},{"period":"3month","weight":-0.215},{"period":"6month","weight":0.1255},{"period":"1year","weight":-0.1129},{"period":"ytd","weight":-0.2016}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0017},{"period":"3month","weight":0.0177},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.0107}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Pelthos Therapeutics Inc.是一家于2021年3月19日成立的内华达公司。该公司是一家临床阶段的生物技术公司,专注于开发和商业化缓解疼痛的新疗法。该公司的临床重点是选择性靶向钠离子通道,即“NaV1.7”,以及NaV家族中的其他受体。NaV1.7在人类生理学中已被基因验证为疼痛受体。遗传学研究表明,具有某种遗传性NaV1.7调节的家庭始终表现出不感到疼痛的病理学。","exchange":"AMEX","name":"PELTHOS THERAPEUTICS INC","nameEN":"PELTHOS THERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PELTHOS THERAPEUTICS INC(PTHS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PELTHOS THERAPEUTICS INC(PTHS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PELTHOS THERAPEUTICS INC,PTHS,PELTHOS THERAPEUTICS INC股票,PELTHOS THERAPEUTICS INC股票老虎,PELTHOS THERAPEUTICS INC股票老虎国际,PELTHOS THERAPEUTICS INC行情,PELTHOS THERAPEUTICS INC股票行情,PELTHOS THERAPEUTICS INC股价,PELTHOS THERAPEUTICS INC股市,PELTHOS THERAPEUTICS INC股票价格,PELTHOS THERAPEUTICS INC股票交易,PELTHOS THERAPEUTICS INC股票购买,PELTHOS THERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PELTHOS THERAPEUTICS INC(PTHS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PELTHOS THERAPEUTICS INC(PTHS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}